Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals' Lorcaserin Achieved Statistically Significant Weight Loss

Arena Pharmaceuticals ARNA today presented meta-analyses of the three trials in the lorcaserin Phase 3 clinical trial program at ECO 2011, the 18th European Congress on Obesity. The analyses show that lorcaserin caused statistically significant weight loss compared to placebo at one year among 7,500 obese and overweight, diabetic and non-diabetic adults. The lorcaserin-mediated weight loss was associated with favorable changes in biomarkers that may be predictive of cardiovascular and metabolic risk and in quality of life. Christen M. Anderson, M.D., Ph.D., Arena's Vice President, Lorcaserin Development, stated, "We are pleased to have the opportunity to share and discuss the results from the lorcaserin Phase 3 program with the European medical community at ECO, and we look forward to submitting a Marketing Authorization Application for regulatory approval of lorcaserin in Europe next year."